Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
Abstract Introduction Pyroglutamate‐modified amyloid β (AβpE3) could be a biomarker for Aβ plaque pathology in the brain. An ultra‐high‐sensitive assay is needed for detecting AβpE3‐40. Methods Immunomagnetic reduction was used for quantification of AβpE3‐40 in plasma from 46 participants. The conce...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| Online Access: | https://doi.org/10.1002/dad2.12029 |